Title : Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.

Pub. Date : 2020 Feb

PMID : 31884128






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: Tyrosine kinase inhibitor (TKI) has been the standard of care for advanced non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, but these tumors invariably develop drug resistance. Tyrosine epidermal growth factor receptor Homo sapiens
2 OBJECTIVES: Tyrosine kinase inhibitor (TKI) has been the standard of care for advanced non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, but these tumors invariably develop drug resistance. Tyrosine epidermal growth factor receptor Homo sapiens